355 related articles for article (PubMed ID: 19364933)
21. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.
Nashan B; Light S; Hardie IR; Lin A; Johnson JR
Transplantation; 1999 Jan; 67(1):110-5. PubMed ID: 9921806
[TBL] [Abstract][Full Text] [Related]
22. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.
Van Assche G; Sandborn WJ; Feagan BG; Salzberg BA; Silvers D; Monroe PS; Pandak WM; Anderson FH; Valentine JF; Wild GE; Geenen DJ; Sprague R; Targan SR; Rutgeerts P; Vexler V; Young D; Shames RS
Gut; 2006 Nov; 55(11):1568-74. PubMed ID: 16603634
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on anti-CD25: daclizumab in MS.
Schippling DS; Martin R
Int MS J; 2008 Sep; 15(3):94-8. PubMed ID: 18808743
[TBL] [Abstract][Full Text] [Related]
24. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.
Busse WW; Israel E; Nelson HS; Baker JW; Charous BL; Young DY; Vexler V; Shames RS;
Am J Respir Crit Care Med; 2008 Nov; 178(10):1002-8. PubMed ID: 18787222
[TBL] [Abstract][Full Text] [Related]
25. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
26. High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.
Yeh S; Wroblewski K; Buggage R; Li Z; Kurup SK; Sen HN; Dahr S; Sran P; Reed GF; Robinson R; Ragheb JA; Waldmann TA; Nussenblatt RB
J Autoimmun; 2008 Sep; 31(2):91-7. PubMed ID: 18571896
[TBL] [Abstract][Full Text] [Related]
27. Daclizumab in multiple sclerosis.
Perez-Miralles FC
Rev Neurol; 2018 Apr; 66(8):271-282. PubMed ID: 29645071
[TBL] [Abstract][Full Text] [Related]
28. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing-remitting multiple sclerosis.
Rose JW; Giovannoni G; Wiendl H; Gold R; Havrdová E; Kappos L; Selmaj KW; Zhao J; Riester K; Tsao LC; Greenberg SJ
Mult Scler Relat Disord; 2017 Oct; 17():32-40. PubMed ID: 29055471
[TBL] [Abstract][Full Text] [Related]
29. Daclizumab reduces CD25 levels on T cells through monocyte-mediated trogocytosis.
Zhang Y; McClellan M; Efros L; Shi D; Bielekova B; Tang MT; Vexler V; Sheridan JP
Mult Scler; 2014 Feb; 20(2):156-64. PubMed ID: 23846354
[TBL] [Abstract][Full Text] [Related]
30. Daclizumab for the treatment of adults with relapsing forms of multiple sclerosis.
Osherov M; Milo R
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1037-1047. PubMed ID: 28803486
[TBL] [Abstract][Full Text] [Related]
31. Two doses of humanized anti-CD25 antibody in renal transplantation: a preliminary comparative study.
Li J; Li X; Tan M; Lin B; Hou S; Qian W; Li B; Zhang D; Zhou B; Wang H; Zhu T; Guo Y
MAbs; 2009; 1(1):49-55. PubMed ID: 20046574
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis.
Perry JS; Han S; Xu Q; Herman ML; Kennedy LB; Csako G; Bielekova B
Sci Transl Med; 2012 Aug; 4(145):145ra106. PubMed ID: 22855463
[TBL] [Abstract][Full Text] [Related]
33. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
34. Brief communication: Successful treatment of pure red-cell aplasia with an anti-interleukin-2 receptor antibody (daclizumab).
Sloand EM; Scheinberg P; Maciejewski J; Young NS
Ann Intern Med; 2006 Feb; 144(3):181-5. PubMed ID: 16461962
[TBL] [Abstract][Full Text] [Related]
35. Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis.
Martin R
Clin Immunol; 2012 Jan; 142(1):9-14. PubMed ID: 22284868
[TBL] [Abstract][Full Text] [Related]
36. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE.
Cohan S; Kappos L; Giovannoni G; Wiendl H; Selmaj K; Havrdová EK; Rose J; Greenberg S; Phillips G; Ma W; Wang P; Lima G; Sabatella G
Mult Scler; 2018 Dec; 24(14):1883-1891. PubMed ID: 28984179
[TBL] [Abstract][Full Text] [Related]
38. Intravenous daclizumab for recalcitrant ocular inflammatory disease.
Bhat P; Castañeda-Cervantes RA; Doctor PP; Foster CS
Graefes Arch Clin Exp Ophthalmol; 2009 May; 247(5):687-92. PubMed ID: 19198869
[TBL] [Abstract][Full Text] [Related]
39. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25.
Chen J; Zhang M; Ju W; Waldmann TA
Blood; 2009 Feb; 113(6):1287-93. PubMed ID: 18948574
[TBL] [Abstract][Full Text] [Related]
40. Daclizumab in treatment of multiple sclerosis patients.
Ali EN; Healy BC; Stazzone LA; Brown BA; Weiner HL; Khoury SJ
Mult Scler; 2009 Feb; 15(2):272-4. PubMed ID: 19136546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
